Get to know our clinical trials
Trial to evaluate the efficacy, safety and tolerability of rocatinlimab (AMG 451) in monotherapy in adult subjects with moderate to severe atopic dermatitis (AD).
THE STUDY IS DESIGNED TO CONFIRM WHETHER ROCATINLIMAB IS EFFECTIVE IN TREATING PATIENTS WITH MODERATE TO SEVERE AD WHO HAVE NOT RESPONDED TO TOPICAL (APPLIED EXTERNALLY TO THE SKIN) OR OTHER TREATMENTS AND WHETHER IT IS EFFECTIVE, WELL TOLERATED AND CAUSES ANY SIDE EFFECTS.
Technical Summary
- 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ROCATINLIMAB (AMG 451) IN MONOTHERAPY IN ADULT SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) (ROCKET-HORIZON).
- Code EudraCT: 2022-000937-18
- Protocol number: 20210143
- Promoter: Amgen, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.